Activity, damage and outcome in systemic vasculitis

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 2, 2001, Pages 225-238

  Carruthers, David ^a   Bacon, Paul ^b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Activity index; Birmingham Vasculitis Activity Score (BVAS); Damage index; Disease extent index; Five factor score; Outcome criteria; Systemic vasculitis; Vasculitis Damage Index (VDI)

Indexed keywords

ACCURACY; CHRONIC DISEASE; DAILY LIFE ACTIVITY; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EMOTION; EMPLOYMENT; FEASIBILITY STUDY; FUNCTIONAL ASSESSMENT; HUMAN; INJURY; MORBIDITY; MORTALITY; ORGAN; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL ENVIRONMENT; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REPRODUCIBILITY; REVIEW; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL; SYSTEMIC VASCULITIS; VALIDATION PROCESS; WEGENER GRANULOMATOSIS;

EID: 0034988996     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2000.0141     Document Type: Article

References (47)

1. Epidemiology of systemic vasculitis - Changing incidence or definition
2. Polyarteritis nodosa
3. Giant cell granuloma of the respiratory tract (Wegener's Granulomatosis)
4. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa
5. Cyclophosphamide therapy of severe systemic necrotising vasculitis
6. Criteria for rheumatic disease - Different types and different functions
7. Measurement of patient outcome in arthritis
8. The American College of Rheumatology 1990 criteria for the classification of vasculitis - Summary
9. Nomenclature of systemic vasculitides - Proposal of an international consensus conference
10. Relapses in patients with a systemic vasculitis
11. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis
12. Wegener granulomatosis - An analysis of 158 patients
13. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus
14. Criteria for disease activity in Wegener's granulomatosis: A requirement for longitudinal clinical studies
15. Validity of a vasculitis activity index for systemic necrotising vasculitis
16. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis
17. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
18. A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (cycazarem)
19. Disease assessment of the vasculitides
20. Modified BVAS for Wegener's granulomatosis
21. Vasculitis assessment for clinical trials
22. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: Potential markers for disease activity
23. Differential B- and T-cell activation in Wegener's granulomatosis
24. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotising vasculitis
25. Clinical significance of antiproteinase 3 antibody positivity in cANCA-positive patients
26. Outcome of polyarteritis nodosa and Churg-Strauss syndrome - An analysis of 25 patients
27. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides
28. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI)
29. Damage occurs early in systemic vasculitis and is an index of outcome
30. Wegener's granulomatosis. Anatomic correlates, a proposed classification
31. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
32. Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin
33. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: A study in 165 patients
34. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients
35. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)
36. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa
37. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides
38. Microscopic polyangiitis - Clinical and laboratory findings in eighty-five patients
39. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome: Analysis of 4 prospective trials including 278 patients
40. The MOS 36-item short-form health survey (SF-36) I: Conceptual framework and item selection
41. VITAL assessment of vasculitis
42. Functional assessment in vasculitis using the SF-36
43. Functional outcome vs damage in systemic vasculitis
44. Activation of granulocytes by antineutrophil cytoplasmic antibodies (ANCA): A Fc gamma RII-dependent process
45. Patients with damage from primary systemic vasculitis experience impaired physical health as measured by the SF36
46. Wegener's granulomatosis - Patient-reported effects of disease on health, function and income
47. Comparison of Dutch and US patients perspective of the effects of Wegener's granulomatosis on health, function, income and interpersonal relationships: Comment on the article by Hoffman et al